ImageneBio, Inc. IMA
ImageneBio, Inc. (Nasdaq: IMA) is an immunology/inflammation drug developer. Its lead program, IMG-007 (olevaprubart), is in Phase 2 for Moderate-to-severe atopic dermatitis. Its next catalyst on record is IMG-007: Alopecia areata Phase 2 initiation (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: IMG-007 — Alopecia areata Phase 2 initiation (2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| IMG-007 (olevaprubart, anti-OX40) | Atopic dermatitis (Phase 2b) | antibody | Phase 2 |
| IMG-007 (olevaprubart) | Alopecia areata (Phase 2) | antibody | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.